arrow
M

Michael Wang

united states department of energy (doe)
H指数:32
被引数:3,555

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B
2023-02-23146
OA
Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A
2023-02-23107
OA
Eptacog beta efficacy and safety in the treatment and control of bleeding in paediatric subjects (<12 years) with haemophilia A or B with inhibitors

使用抑制剂治疗和控制血友病A或B的儿科受试者 (<12岁) 出血的Eptacog beta功效和安全性

2022-04-279
OA
The safety of activated eptacog beta in the management of bleeding episodes and perioperative haemostasis in adult and paediatric haemophilia patients with inhibitors

活化的eptacog β 在使用抑制剂的成人和儿童血友病患者的出血发作和围手术期止血管理中的安全性

2021-10-1110
OA
PERSEPT 3: A phase 3 clinical trial to evaluate the haemostatic efficacy of eptacog beta (recombinant human FVIIa) in perioperative care in subjects with haemophilia A or B with inhibitors
2021-10-068
OA
A Safe Transitions Pathway for post-craniotomy neurological surgery patients: high-value care that bypasses the intensive care unit
2021-05-0115
OA
Real-world data of immune tolerance induction using recombinant factor VIII Fc fusion protein in patients with severe haemophilia A with inhibitors at high risk for immune tolerance induction failure: A follow-up retrospective analysis

使用重组因子VIII Fc融合蛋白诱导免疫耐受的真实世界数据在具有免疫耐受诱导失败高风险的抑制剂的严重a型血友病患者中: 随访回顾性分析

2020-11-1810
OAAI
Real-world data demonstrate improved bleed control and extended dosing intervals for patients with haemophilia B after switching to recombinant factor IX Fc fusion protein (rFIXFc) for up to 5 years

实际数据表明,在改用重组因子IX Fc融合蛋白 (rFIXFc) 长达5年后,血友病B患者的出血控制得到改善,给药间隔延长

2020-10-0414
OAAI